Oracea (Doxycycline)

Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, which stops aminoacyl‑tRNA from attaching to the ribosome. In addition to its antibacterial activity, it modulates inflammatory pathways by decreasing matrix metalloproteinases and neutrophil chemotaxis, thereby improving rosacea symptoms.

The specific dose of Oracea is determined by the prescribing clinician based on the individual patient's condition, severity of rosacea, and any relevant medical factors. The product is supplied as a 40 mg delayed‑release tablet, and the prescriber will set the appropriate dosing schedule.

Oracea is classified as Pregnancy Category D, meaning it should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. It is excreted in breast milk, so breastfeeding is not recommended unless the benefit to the mother outweighs the possible risk to the infant.

To request Oracea, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details and any necessary import documentation.

Oracea (oral doxycycline) offers systemic anti‑inflammatory and antibacterial effects, whereas topical agents such as metronidazole or azelaic acid act locally on the skin. Oral doxycycline can address widespread or resistant lesions and provides a convenient once‑daily regimen, but it carries systemic safety considerations that topical therapies typically avoid.

Oracea tablets should be stored at ambient temperature, below 25 °C, in their original blister or bottle to protect from moisture. Keep the product out of direct sunlight and away from children. No refrigeration is required.

Oracea is taken orally as a delayed‑release tablet, usually with a full glass of water. The tablet should be swallowed whole and not crushed or chewed to maintain its extended‑release properties. Patients should follow the dosing schedule prescribed by their healthcare professional.

Serious adverse events include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome or toxic epidermal necrolysis, and Clostridioides difficile‑associated colitis. Intracranial hypertension and significant liver injury have also been reported. Patients should seek immediate medical attention if they experience rash, fever, persistent vomiting, severe abdominal pain, visual changes or jaundice.

Oracea is contraindicated in individuals with known hypersensitivity to doxycycline, other tetracyclines, or any component of the formulation. It should also be avoided in patients with severe renal impairment unless dose‑adjusted, and in those who are pregnant or breastfeeding unless the prescriber determines that the benefits outweigh the risks.